Our data showed that benzyl‐α‐GalNAc treatment decreased the molecular weight of TYRO3 and MERTK (Fig. S5), suggesting that O‐glycans are also present in TYRO3 and MERTK in colon cancer cells. This evidence concerns the gene TYRO3 and malignant colon neoplasm.